The Technical AnalystExchange: HKSE Sector: Pharmaceuticals Industry: Drug Manufacturers—Specialty & Generic
PuraPharm Corp Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.33% HKD0.760
America/New_York / 3 mai 2024 @ 02:21
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 300.24 mill |
| EPS: | -0.270 |
| P/E: | -2.81 |
| Earnings Date: | Mar 28, 2024 |
| SharesOutstanding: | 395.05 mill |
| Avg Daily Volume: | 0.0614 mill |
| RATING 2024-05-02 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.81 | sector: PE 23.82 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.21x |
| Company: PE -2.81 | industry: PE 13.09 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD-0.625 (-182.27%) HKD-1.385 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
HKD 0.722 - 0.798 ( +/- 5.00%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | HKD0.760 (1.33% ) |
| Volume | 0.0410 mill |
| Avg. Vol. | 0.0614 mill |
| % of Avg. Vol | 66.78 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 1498.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
1498.HK
PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Haveron, Oncozac, and Immuzac names. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provide Chinese medicine services and concentrated Chinese medicine granules products. In addition, the company engages in the plantation and trading of raw Chinese herbs; and manufacture and sale of traditional Chinese medicine decoction pieces. Further, it provides modernized Chinese medicine services; and Chinese medical diagnostic services. The company sells its products to hospitals, healthcare institutions, and medicine practitioners, as well as operates an online store. It operates 43 Nong's clinics in Hong Kong and 1 Nong's clinic in Guangxi, China. The company was founded in 1998 and is headquartered in Tai Po, Hong Kong.